Venus Medtech (Hangzhou) Inc. (HKG:2500)

Market Cap	1.12B
Revenue (ttm)	501.05M
Net Income (ttm)	-760.15M
Shares Out	441.01M
EPS (ttm)	-1.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,416,000
Average Volume	755,475
Open	5.70
Previous Close	5.62
Day's Range	5.50 - 5.94
52-Week Range	5.50 - 5.94
Beta	0.86
RSI	64.93
Earnings Date	Aug 29, 2025

About Venus Medtech (Hangzhou)

Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, clinical development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, and VenusA-Pro; and VenusP-Valve is a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also de...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2009
• Employees: 691
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2500

Financial Performance

In 2024, Venus Medtech (Hangzhou)'s revenue was 470.83 million, a decrease of -4.18% compared to the previous year's 491.37 million. Losses were -714.31 million, 1.50% more than in 2023.

Financial numbers in CNY